免疫疗法与SCLC生存结果相关的序列:对国家癌症数据库的分析

Dan Yao1, Yinting Liu2, Wenyao Yu3

  • 1Division of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou Key Laboratory of Heart and Lung, Wenzhou 325000, China.

Cancers
|February 27, 2026
PubMed
概括

对于扩散阶段的小细胞肺癌 (SCLC),通过化学疗法或化学辐射疗法 (CRT) 启动免疫疗法可以改善存活率. 在CRT后免疫治疗的最佳时间可能在4-7天内获得最大益处.

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805